Anti-BTK (phospho Y223) antibody [EP420Y]

• Supplier: Abcam
• Catalog: ab68217
• Prices: $384.00
• Sizes: 100 µl
• Host: Rabbit
• Clonality: Monoclonal
• Isotype: IgG
• Clone: EP420Y
• Applications: WB IP
• Species Reactivities: Human, Mouse, Rat
• Antigen: Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human BTK
• Description: Rabbit Monoclonal
• Gene: BTK
• Conjugate: Unconjugated

Product images

All lanes : Anti-BTK (phospho Y223) antibody [EP420Y] (ab68217) at 1/10000 dilution (purified)Lane 1 : Untreated K562 cell lysateLane 2 : K562 cells treated with pervanadateLysates/proteins at 10 µg per lane.SecondaryHRP goat anti-rabbit (H+L) at 1/1000 dilution

ab68217 (purified) at 1/50 immunoprecipitating BTK (phospho Y223) in Ramos cells (Lane 1). For western blotting, a HRP-conjugated anti-rabbit IgG (H+L) was used as the secondary antibody (1/1000).Blocking buffer and concentration: 5% NFDM/TBST.Diluting buffer and concentration: 5% NFDM /TBST.

All lanes : Anti-BTK (phospho Y223) antibody [EP420Y] (ab68217) at 1/500000 dilution (unpurified)Lane 1 : Ramos cell lysates, cells un-treatedLane 2 : Ramos cell lysates, cells treated with pervanadateLysates/proteins at 10 µg per lane.SecondaryHRP labelled goat anti-rabbit at 1/2000 dilution

Product References

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. - Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor.

Guo W, Liu R, Bhardwaj G, Yang JC, Changou C, Ma AH, Mazloom A, Chintapalli S, Xiao K, Xiao W, Kumaresan P, Sanchez E, Yeh CT, Evans CP, Patterson R, Lam KS, Kung HJ. Cell Death Dis. 2014 Sep 4;5:e1409.

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by - A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by

Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, Anderson KC, Hunter ZR, Treon SP. Blood. 2013 Aug 15;122(7):1222-32.

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of - Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of

Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, Witowski SR, Lounsbury H, Chaturvedi P, Mazdiyasni H, Zhu Z, Nacht M, Freed MI, Petter RC, Dubrovskiy A, Singh J, Westlin WF. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally - Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally

Liao C, Hsu J, Kim Y, Hu DQ, Xu D, Zhang J, Pashine A, Menke J, Whittard T, Romero N, Truitt T, Slade M, Lukacs C, Hermann J, Zhou M, Lucas M, Narula S, DeMartino J, Tan SL. Arthritis Res Ther. 2013 Oct 4;15(5):R146.